ArticleACS nano2024
Deep Learning-Enhanced Paper-Based Vertical Flow Assay for High-Sensitivity Troponin Detection Using Nanoparticle Amplification.
Article in ACS nano, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Colorimetric/chemiluminescent vertical flow immunoassay based on multifunctional cobalt-gold bimetallic nanoclusters for Brucella antibody detection and deep learning-assisted semiquantitative analysis.Mikrochimica acta · 2026Article
- Article
- A review of bloodstream infections-pathogens, pathogenesis, diagnostic strategies, treatment methods-challenges and future aspects.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Review
- Article
- Clinical Applications of Blood-Derived Extracellular Vesicle Biomarkers in Breast Cancer: A Scoping Review.International journal of molecular sciences · 2026Article
- Review
- Deep learning-enhanced dual-mode multiplexed optical sensor for point-of-care diagnostics of cardiovascular diseases.Light, science & applications · 2026Article
- High Sensitivity Cardiac Troponin I Detection via MP-Locked Aptamer and Multimeric DNAzyme-Coupled Hyperbranched Hybridization Chain Reaction.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Advances in nanomaterials for the diagnosis and treatment of ischemic heart disease.Discover nano · 2026Review
- Relationship Between Cumulative Exposure of Lactate Dehydrogenase Concentrations and Major Adverse Cardiac and Cerebrovascular Events in Hypertensive Patients: A Retrospective Cohort Study from Northwest China.Journal of inflammation research · 2026Article
- Advancements and Applications of Lateral Flow Assays (LFAs): A Comprehensive Review.Sensors (Basel, Switzerland) · 2025Review
- Research progress on nanomaterial-empowered electrochemical biosensors for the detection of cardiac troponin I.RSC advances · 2025Review
- Recent Advances in Monitoring Technologies for Cardiac Troponin I: A Pivotal Biomarker in Cardiovascular Diseases.Biomolecules · 2025Review
- Sample-sparing multiplexed antibody Fc biomarker discovery using a reconfigurable integrated microfluidic platform.Lab on a chip · 2025Article
- Paper-Based Vertical Flow Assays for in Vitro Diagnostics and Environmental Monitoring.ACS sensors · 2025Review
- Machine learning in point-of-care testing: innovations, challenges, and opportunities.Nature communications · 2025Review
- Deep Learning-Enhanced Chemiluminescence Vertical Flow Assay for High-Sensitivity Cardiac Troponin I Testing.Small (Weinheim an der Bergstrasse, Germany) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Successful integration of point-of-care testing (POCT) into clinical settings requires improved assay sensitivity and precision to match laboratory standards. Here, we show how innovations in amplified biosensing, imaging, and data processing, coupled with deep learning, can help improve POCT. To demonstrate the performance of our approach, we present a rapid and cost-effective paper-based high-sensitivity vertical flow assay (hs-VFA) for quantitative measurement of cardiac troponin I (cTnI), a biomarker widely used for measuring acute cardiac damage and assessing cardiovascular risk. The hs-VFA includes a colorimetric paper-based sensor, a portable reader with time-lapse imaging, and computational algorithms for digital assay validation and outlier detection. Operating at the level of a rapid at-home test, the hs-VFA enabled the accurate quantification of cTnI using 50 μL of serum within 15 min per test and achieved a detection limit of 0.2 pg/mL, enabled by gold ion amplification chemistry and time-lapse imaging. It also achieved high precision with a coefficient of variation of <7% and a very large dynamic range, covering cTnI concentrations over 6 orders of magnitude, up to 100 ng/mL, satisfying clinical requirements. In blinded testing, this computational hs-VFA platform accurately quantified cTnI levels in patient samples and showed a strong correlation with the ground truth values obtained by a benchtop clinical analyzer. This nanoparticle amplification-based computational hs-VFA platform can democratize access to high-sensitivity point-of-care diagnostics and provide a cost-effective alternative to laboratory-based biomarker testing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.